Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility

Experimental Cell Research

Volumn 258, Issue 2, 2000, Pages 237-244

  Chazaud, Bénédicte ^a   Bonavaud, Sylvie ^b   Plonquet, Anne ^c   Pouchelet, Marcel ^d   Gherardi, Romain K ^a   Barlovatz Meimon, Georgia ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d INSERM   (France)

Author keywords

LRP; Migration; Myogenic cells; Plasminogen activator system; Urokinase

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CELL MOTILITY; CINERADIOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; MUSCLE CELL; PRIORITY JOURNAL;

EID: 0034255623     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.4934     Document Type: Article

References (50)

1. Quigley J. P., Berkenpas M. B., Aimes R. T., Chen J. M. Serine protease and metalloprotease cascade systems involved in pericellular proteolysis. Cell. Differ. Dev. 32:1990;263-275.
2. Blasi F. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today. 18:1997;415-417.
3. Mignatti P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int. 47:1995;S12-S14.
4. Vassalli J. D., Sapino A. P., Belin D. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1991;1067-1072.
5. Plow E. F., Herren T., Redlitz A., Miles L. A., Hoover-Plow J. L. The cell biology of the plasminogen system. FASEB J. 9:1995;939-945.
6. Basbaum C. B., Werb Z. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr. Opin. Cell Biol. 8:1996;731-738.
7. Preissner K. T., Grulich-Henn J., Ehrlich H. J., Declerck P., Justus C., Collen D., Pannekoek H., Muller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J. Biol. Chem. 265:1990;18490-18498.
8. Lawrence D. A., Palaniappan S., Stefansson S., Olson S. T., Francis-Chmura A. M., Shore J. D., Ginsburg D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. J. Biol. Chem. 272:1997;767-7680.
9. 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. J. Biol. Chem. 267:1992;14543-14546.
10. Andreasen P. A., Sottrup-Jensen L., Kjoller L., Nykjaer A., Moestrup S. K., Petersen C. M., Gliemann J. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338:1994;239-245.
11. 2-Macroglobulin receptor/LDL receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131:1995;1609-1622.
12. Nykjaer A., Conese M., Christensen E. I., Olson D., Cremona O., Gliemann J., Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16:1997;2610-2620.
13. Moestrup S. K., Nielsen S., Andreasen P., Jorgensen K. E., Nykjaer A., Roigaard H., Gliemann J., Christensen E. I. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J. Biol. Chem. 268:1993;16564-16570.
14. Stefansson S., Kounnas M. Z., Henkin J., Mallampalli R. K., Chappell D. A., Strickland D. K., Argraves W. S. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. J. Cell Sci. 108:1995;2361-2368.
15. Argraves K. M., Battey F. D., MacCalman C. D., McCrae K. R., Gafvels M., Kozarsky K. F., Chappelle D. A., Strauss J. F. 3rd, Strickland D. K. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. Biol. Chem. 270:1995;26550-26557.
16. Heegaard C. W., Simonsen A. C., Oka K., Kjoller L., Christensen A., Madsen B., Ellgaard L., Chan L., Andreasen P. A. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J. Biol. Chem. 270:1995;20855-20861.
17. Stefansson S., Lawrence D. A. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature. 383:1996;441-443.
18. Stahl A., Mueller B. M. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. Int. J. Cancer. 71:1997;116-122.
19. Kjoller L., Kanse S. M., Kirkegaard T., Rodenburg K. W., Ronne E., Goodman S. L., Preissner K. T., Ossowski L., Andreasen P. A. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independent of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232:1997;420-429.
20. Waltz D., Natkin L. R., Fujita R. M., Wei Y., Chapman H. A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100:1997;58-67.
21. Bonavaud S., Charriere-Bertrand C., Rey C., Leibovitch M., Pedersen N., Frisdal E., Planus E., Blasi F., Gherardi R., Barlovatz-Meimon G. Evidence of a non conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. J. Cell Sci. 110:1997;1083-1089.
22. Bonavaud S., Thibert P., Gherardi R. K., Barlovatz-Meimon G. Primary human muscle satellite cell culture: Variations of cell yield, proliferation and differentiation according to age and sex of donors, site of muscle biopsy, and delay before processing. Biol. Cell. 89:1997;233-240.
23. Planus E., Barlovatz-Meimon G., Rogers R. A., Bonavaud S., Ingber D. E., Wang N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci. 110:1997;1091-1098.
24. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J. S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53:1993;4143-4147.
25. Chucholowski N., Schmitt M., Rettenberger P., Schüren E., Moniwa N., Goretzki L., Wilhelm O., Weidel U., Jänicke F., Graeff H. Flow cytometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936. Fibrinolysis. 6:1992;95-102.
26. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52:1992;3610-3614.
27. Torr-Brown S. R., Sobel B. E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 72:1993;413-421.
28. Argraves K. M., Kozarsky K. F., Fallon J. T., Harpel P. C., Strickland D. K. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J. Clin. Invest. 100:1997;2170-2181.
29. Authier F. J., Chazaud B., Plonquet A., Eliezer-Vanerot M.-C., Poron F., Bélec L., Barlovatz-Meimon G., Gherardi R. K. Differential expression of the interleukin-1 system components during in vitro myogenesis - Implication of IL-1β in induction of myogenic cell apoptosis. Cell Death Differ. 6:1999;1012-1021.
30. Chazaud B., Christov C., Gherardi R. K., Barlovatz-Meimon G. In vitro evaluation of human muscle satellite cell migration prior to fusion into myotubes. J. Muscle Res. Cell Motil. 19:1998;931-936.
31. Quax P. H. A., Frisdal E., Pedersen N., Bonavaud S., Thibert P., Martelly I., Verheijen J. H., Blasi F., Barlovatz-Meimon G. Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro. Dev. Biol. 151:1992;166-175.
32. Opas M. Cellular adhesiveness, contractility, and traction: Stick, grip and slip control. Biochem. Cell Biol. 73:1995;311-316.
33. Lauffenburger D. A., Horwitz A. F. Cell migration: A physically integrated molecular process. Cell. 84:1996;359-369.
34. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:1996;697-715.
35. Burridge K., Chrzanowska-Wodnicka M. Focal adhesions, contractility and signaling. Annu. Rev. Cell Dev. Biol. 12:1996;463-519.
36. Ingber D. E. Tensegrity: The architecture basis of cellular mechanotransduction. Annu. Rev. Physiol. 59:1997;575-599.
37. Andreasen P. A., Kjoller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer. 72:1997;1-22.
38. Felding-Haberman B., Cheresh D. A. Vitronectin and its receptors. Curr. Opin. Cell Biol. 5:1993;864-868.
39. Waltz D. A., Chapman H. A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269:1994;14746-14750.
40. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., Chapman H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380-32388.
41. Moser T. L., Enghild J. J., Pizzo S. V., Stack M. S. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J. 307:1995;867-873.
42. Kanse S. M., Kost C., Wilhelm O. G., Andreasen P. A., Preissner K. T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224:1996;344-353.
43. Deng G., Curriden S. A., Wang S., Rosenberg S., Loskutoff D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1996;1563-1571.
44. Chapman H. A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:1997;714-724.
45. Stefansson S., Muhammad S., Cheng X. F., Battey F. D., Strickland D. K., Lawrence D. A. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J. Biol. Chem. 273:1998;6358-6366.
46. Wang N., Planus E., Pouchelet M., Fredberg J. J., Barlovatz-Meimon G. Urokinase receptor mediates mechanical force transfer across the cell surface. Am. J. Physiol. 268:1995;C1062-C1066.
47. Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. BioEssays. 15:1993;105-111.
48. Lijnen H. R., De Cock F., Collen D. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the uPA receptor. FEBS Lett. 224:1994;567-574.
49. Maheshwari G., Lauffenburger D. Deconstructing (and reconstructing) cell migration. Microsc. Res. Techn. 43:1998;358-368.
50. Mitchison T. J., Cramer L. P. Actin-based cell motility and cell locomotion. Cell. 84:1996;371-379.